Canada has a law that prohibits claiming a product works unless you tested it first. It carries penalties up to ten million dollars. It applies to devices. It does not care what Health Canada thinks. In twenty years it has been used against three health devices, all of them for weight loss.
Everywhere else in this section, the obstacle is jurisdiction. Health Canada's device regime reaches manufacturers and importers but stops at the clinic door. The naturopathic colleges reach practitioners but have published almost nothing. Both gaps are structural, and neither agency chose them.
The Competition Bureau is a different problem. Its jurisdiction fits these devices better than anyone's, and it has barely used it.
Paragraph 74.01(1)(b) of the Competition Act prohibits any claim about a product's performance, effectiveness or length of life unless the claim is based on an adequate and proper test — and the test must have been done before the claim was made. Section 52 creates a parallel criminal offence for false or misleading representations made knowingly or recklessly.
Four features make this the best-fitting instrument in Canadian law for the devices documented on this site:
| Date | Respondent | Device | Outcome |
|---|---|---|---|
| Application June 2005; Tribunal decision 25 Sept 2006 | Gestion Finance Tamalia Inc. and Sylvain Leblanc, operating Les Centres de Santé Minceur (Quebec) | Cellotherm — a weight-loss apparatus, marketed with the natural products Cure de départ, Nocto Slim and Nopasim | Tribunal found numerous false and misleading representations — that the device produced localised weight loss, achieved the effect of liposuction without surgery, and helped dissolve fat. Administrative penalties of $50,000 against the company and $20,000 against Leblanc, plus a 10-year prohibition order. |
| 10 Jan 2018 | Thane Canada Inc. | AbTronic X2 and Ab Command iX2 — electronic muscle stimulation belts | Claims such as losing fifteen pounds and thirteen inches in eight weeks led consumers to believe the devices produced weight loss and body contouring without diet or exercise. The Bureau concluded the claims were false or misleading and not based on adequate and proper testing. $350,000 administrative monetary penalty and a 10-year ban on marketing these or similar devices in Canada. The largest device penalty on this list. |
| April–May 2020 | Unnamed — a national retailer and businesses in B.C., Alberta, Saskatchewan, Ontario, Quebec and New Brunswick | Masks, air filters and purifiers, UV and ozone air sterilisation systems | 17 compliance warnings over untested claims that the products would kill or filter out the COVID-19 virus. Most businesses pulled the products or dropped the claims. Warnings only — no penalties, no orders, and no respondent was named publicly. |
For contrast, the Bureau's most-publicised health file of the last decade was not a device at all. After a February 2019 warning to the natural health products industry about weight-loss claims, it moved against NuvoCare Health Sciences Inc. and its chief executive — a temporary consent agreement in May 2020, and a final settlement registered with the Competition Tribunal in April 2022, binding for ten years, requiring a corporate compliance programme. The products were licensed by Health Canada, but not licensed to make the weight-loss claims that were being made for them.
| Device class | Bureau action | Notes |
|---|---|---|
| EAV / electrodermal screening — Vegatest, Vistron, BioMeridian, ZYTO, Asyra | None found | Sold in Canada today at listed prices with advertised performance claims. Two published double-blind studies found the method could not distinguish allergic from non-allergic subjects — which is to say the adequate-and-proper-testing question has already been answered, in public, against the devices. |
| Breast thermography — DITI | None found | Advertised for years as detecting cancer years before mammography. Health Canada has said four times that it knows of no clinical evidence supporting the screening use. No performance-claim proceeding has followed. |
| Zapper and Syncrometer | None found | The US Federal Trade Commission — the Bureau's closest American counterpart — pleaded both as devices in 2003 and obtained an order and consumer refunds. Canada was a partner in the campaign but brought nothing. |
| Bioresonance — MORA, BICOM, GSR-series instruments | None found | Sold with training packages through the channel described in The supply chain. |
| Bioelectrical impedance (BIA) marketed as a diagnostic | None found | See the section below — this one is not like the others, and the difference matters. |
What BIA actually supports is narrower than its marketing:
This is the reason BIA belongs in this section despite being real, and it is worth following carefully.
Because genuine impedance devices have been cleared for genuine purposes, a manufacturer of something else can borrow the vocabulary and the regulatory paperwork. The Electro Interstitial Scan is the clearest instance. Regulators have cleared impedance plethysmograph devices that assess regional blood flow or body fat. A device intended instead to diagnose a wide range of health problems is a different product requiring a different and far higher approval — and Quackwatch's review found the EIS was merely registered, which means only that the agency had been told it exists, and was not in the clearance database.
The same manoeuvre appears in a 2000s FDA warning letter concerning the BodyScan 2010 and VLD-100, which cited a clearance number belonging to a predecessor of the EPFX — a device whose original holder had agreed its labelling would refer only to galvanic skin response, electromyography and skin temperature, and to no medical condition at all. The brochures nonetheless advertised acupuncture meridians, stress imbalances and energy flow, under the heading of an FDA registration.
The Bureau does not deny jurisdiction over health claims. It describes the limits of when it will use it, and the description is the answer to why so little happens.
The sentence continues: the Bureau may act where the general impression created goes beyond what Health Canada expressly approved. It repeated the same formulation when it settled the NuvoCare matter in 2022.
As a division of labour that is defensible, and in the NuvoCare case it worked — licensed products, unlicensed claims, Bureau action. But run it against the devices in this section and it produces a loop:
In March 2024 Health Canada and the Bureau signed a memorandum of understanding to share information and coordinate on false and misleading health claims. It is the right instrument. It is also two years old, and no proceeding concerning any device in this section has emerged from it.
One correction is worth recording, because it did not come from a regulator.
Around 2012, science-advocacy writers — notably Dianne Sousa at Skeptic North, whose work was picked up by Science-Based Pharmacy — systematically documented the credentials and claims behind “Registered Holistic Allergist” designations and bioenergetic allergy-elimination practice in Canada. The designation did not survive the scrutiny.
The pattern recurs across this whole section. The Ontario naturopath advertising thermography who took it down after a Globe and Mail reporter called. The devices whose sellers quietly moved claims off public catalogues. In each case the correction came from publication, not prosecution.
Competition Bureau, “Performance claims not based on an adequate and proper test,” and “False or Misleading Representations and Deceptive Marketing Practices” guidance. • Competition Bureau / Industry Canada news releases: “Competition Bureau challenges weight loss claims made by Quebec companies,” 28 June 2005; “Tribunal decision follows Competition Bureau investigation concerning bogus claims,” 25 September 2006; “False weight loss claims lead to a $350,000 penalty,” 10 January 2018; “Weight loss claims must be true and supported by testing,” 8 February 2019; “Competition Bureau cracking down on deceptive marketing claims about COVID-19 prevention or treatment,” May 2020; “Competition Bureau resolves its concerns in misleading weight loss claims case,” April 2022. • CBC News, “Canadian weight-loss company slapped with fine for misleading advertising,” 25 September 2006, and “Competition bureau joins battle against false COVID-19 claims, issuing warnings,” April 2020. • Health Canada – Competition Bureau Memorandum of Understanding, 7 March 2024. • On bioelectrical impedance: Branco et al., “Bioelectrical Impedance Analysis (BIA) for the Assessment of Body Composition in Oncology: A Scoping Review,” Nutrients 2023;15:4792; published critiques of BIA reproducibility and prediction error; U.S. FDA 510(k) clearance language for the ImpediMed L-Dex U400 (2007) and SOZO (2018). • Quackwatch, “Electro Interstitial Scans: Another Test to Avoid,” and the FDA warning letter to Phazx Systems, Inc. concerning the BodyScan 2010 and VLD-100. • Skeptic North and Science-Based Pharmacy on “Registered Holistic Allergists” and bioenergetic allergy practice, 2012.
Corrections wanted. If the Competition Bureau has taken any action — proceeding, consent agreement, compliance warning or advisory letter — concerning an electrodermal screening device, a breast thermography service, a bioresonance instrument, or a bioimpedance device marketed for diagnosis, QuackeryWatch would like the citation and will add it to the table.